Phagocytic synapse enhancers are developed, a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin, that provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways.
Valerio Sabatino, Cong Tang, Rita C. Acúrcio et al.· Cancer Research· 0 citations
These findings reframe GBM as a driver of neuronal network reorganisation rather than uniform hyperexcitability, and establish a compartmentalised, single-neuron-resolution platform for the longitudinal observation, dissection, and ultimately targeting of the network processes that underlie disease progression.
Giulia Amos, Luc Jordi, K. Ahuja et al.· bioRxiv· 0 citations
Glioblastoma remains one of the most aggressive primary brain tumors in adults, with a survival rarely exceeding 15 months despite multimodal therapy. Novel immunotherapeutic strategies, particularly chimeric antigen receptor T-cell therapy, have emerged as promising approaches to overcome the limitations of convention...
M. Etter, K. Akeret, Raphael Guzman et al.· CNS Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
